Latest news
Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 08:25:24 GMTEbola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens - The Spokesman-ReviewThe Spokesman-Review · Sat, 08 Aug 2026 01:46:22 GMTGilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatchMarketWatch · Fri, 07 Aug 2026 20:36:00 GMTPensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeatMarketBeat · Fri, 07 Aug 2026 10:33:12 GMTNewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD - MarketBeatMarketBeat · Fri, 07 Aug 2026 09:20:52 GMTHIV Progress in Kenya: Building the Bridge to Breakthrough - Gilead SciencesGilead Sciences · Fri, 07 Aug 2026 09:16:23 GMTGilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeatMarketBeat · Fri, 07 Aug 2026 08:32:35 GMTGILEAD SCIENCES, INC. 2026: Revenue $7.8B, EPS ($8.45) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMT